Journal of Clinical Oncology, Vol 16, 2195-2201, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma

BV Taylor, JC Buckner, TL Cascino, JR O'Fallon, PL Schaefer, RP Dinapoli and P Schomberg
Royal Hobart Hospital, Australia.

PURPOSE: The effect of radiotherapy on the long-term cognitive performance of patients treated for intracranial neoplasm is a major concern to clinicians and patients, particularly as long-term survival or cure is possible for a small minority of patients. To assess the effects of cranial radiotherapy and chemotherapy on the cognitive performance of high-grade glioma patients, we analyzed cognitive performance data collected in a series of prospective clinical trials. METHODS: We studied 701 high-grade brain tumor patients entered onto two consecutive North Central Cancer Treatment Group (NCCTG) randomized treatment trials designed to compare radiotherapy and carmustine (BCNU) versus radiotherapy and 1-(2-chloroethyl)-3(2,6 dioxo-l-piperidyl)-1- nitrosource a (PCNU) (first trial) and radiotherapy and BCNU and interferon alfa (IFN) versus radiotherapy and BCNU (second trial). Folstein Mini-Mental Status Exam (MMSE) score and Eastern Cooperative Oncology Group (ECOG) performance score (PS) recorded at baseline and 6, 12, 18, and 24 months were analyzed to assess cognitive and physical function over time. Patients who did not demonstrate tumor progression within 60 days of the assessment time were considered nonprogressors at that evaluation. A loss of greater than 3 points on the MMSE was considered significant deterioration. RESULTS: The number of patients who experienced a greater than 3-point decrease in MMSE from baseline was 13 of 119 nonprogressors (10.9%; 95% confidence interval [CI], 6.3% to 18.9%) at 6 months, three of 54 nonprogressors (5.5%; 95% CI, 0.5% to 12.8%) at 12 months, three of 30 nonprogressors (10%; 95% CI, 2.1% to 26.5%) at 18 months, and four of 22 nonprogressors (18.2%; 95% CI, 5.2% to 40.3%) at 24 months. The CIs at all times overlapped, which indicates no statistically significant increase in the percentage of patients who experienced a significant decrease in their MMSE score. Patients who demonstrated a significant decrease in their MMSE score were significantly older than those who did not (P = .0017) at 6 months and remained so throughout follow-up; moreover, they had a significantly shorter time to progression and death. ECOG PS was strongly negatively correlated with MMSE score throughout the study, and MMSE score at all time intervals was correlated with baseline PS. CONCLUSION: In this population of glioma patients who received radiotherapy, there is no clear trend to cognitive worsening. Factors such as older age, poorer PS, and subclinical tumor progression may be more significant factors in those patients who did demonstrate a significant cognitive decline.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Bosma, J. C. Reijneveld, L. Douw, M. J. Vos, T. J. Postma, N. K. Aaronson, M. Muller, W. P. Vandertop, B. J. Slotman, M. J. B. Taphoorn, et al. Health-related quality of life of long-term high-grade glioma survivors Neuro-oncol, January 1, 2009; 11(1): 51 - 58. [Abstract] [Full Text] [PDF]

				J.-x. Cheng, X. Zhang, and B.-L. Liu Health-related quality of life in patients with high-grade glioma Neuro-oncol, January 1, 2009; 11(1): 41 - 50. [Abstract] [Full Text] [PDF]

				R. Liu, M. Page, K. Solheim, S. Fox, and S. M. Chang Quality of life in adults with brain tumors: Current knowledge and future directions Neuro-oncol, January 1, 2009; 11(3): 330 - 339. [Abstract] [Full Text] [PDF]

				I. Bosma, M. J. Vos, J. J. Heimans, M. J.B. Taphoorn, N. K. Aaronson, T. J. Postma, H. M. van der Ploeg, M. Muller, W. P. Vandertop, Ben. J. Slotman, et al. The course of neurocognitive functioning in high-grade glioma patients Neuro-oncol, January 1, 2007; 9(1): 53 - 62. [Abstract] [Full Text] [PDF]

				P. D. Brown, A. W. Jensen, S. J. Felten, K. V. Ballman, P. L. Schaefer, K. A. Jaeckle, J. H. Cerhan, and J. C. Buckner Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma J. Clin. Oncol., December 1, 2006; 24(34): 5427 - 5433. [Abstract] [Full Text] [PDF]

				J. C. Buckner, K. V. Ballman, J. C. Michalak, G. V. Burton, T. L. Cascino, P. J. Schomberg, R. B. Hawkins, B. W. Scheithauer, H. M. Sandler, R. S. Marks, et al. Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials J. Clin. Oncol., August 20, 2006; 24(24): 3871 - 3879. [Abstract] [Full Text] [PDF]

				J. P. Steinbach, H. -P. Blaicher, U. Herrlinger, W. Wick, T. Nagele, R. Meyermann, M. Tatagiba, M. Bamberg, J. Dichgans, H. -O. Karnath, et al. Surviving glioblastoma for more than 5 years: The patient's perspective Neurology, January 24, 2006; 66(2): 239 - 242. [Abstract] [Full Text] [PDF]

				P. Brown and J. Buckner In Reply: J. Clin. Oncol., March 1, 2004; 22(5): 967 - 968. [Full Text] [PDF]

				P. D. Brown, J. C. Buckner, J. H. Uhm, and E. G. Shaw The neurocognitive effects of radiation in adult low-grade glioma patients Neuro-oncol, July 1, 2003; 5(3): 161 - 167. [Abstract] [PDF]

				P. D. Brown, J. C. Buckner, J. R. O'Fallon, N. L. Iturria, C. A. Brown, B. P. O'Neill, B. W. Scheithauer, R. P. Dinapoli, R. M. Arusell, W. J. Curran, et al. Effects of Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma Measured by the Folstein Mini-Mental State Examination J. Clin. Oncol., July 1, 2003; 21(13): 2519 - 2524. [Abstract] [Full Text] [PDF]

				I. J. Torres, A. J. Mundt, P. J. Sweeney, S. Llanes-Macy, L. Dunaway, M. Castillo, and R. L. Macdonald A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors Neurology, April 8, 2003; 60(7): 1113 - 1118. [Abstract] [Full Text] [PDF]

				L. C. W. Lam, S. F. Leung, and Y. L. Chan Progress of Memory Function After Radiation Therapy in Patients With Nasopharyngeal Carcinoma J Neuropsychiatry Clin Neurosci, February 1, 2003; 15(1): 90 - 97. [Abstract] [Full Text] [PDF]

				M. Klein, M. J.B . Taphoorn, J. J. Heimans, H. M. van der Ploeg, W. P. Vandertop, E. F. Smit, S. Leenstra, C. A.F. Tulleken, W. Boogerd, J. S.A. Belderbos, et al. Neurobehavioral Status and Health-Related Quality of Life in Newly Diagnosed High-Grade Glioma Patients J. Clin. Oncol., October 15, 2001; 19(20): 4037 - 4047. [Abstract] [Full Text] [PDF]

				C. A. Meyers, K. R. Hess, W. K. A. Yung, and V. A. Levin Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma J. Clin. Oncol., February 1, 2000; 18(3): 646 - 646. [Abstract] [Full Text] [PDF]

				B. P. O'Neill, C.-H. Wang, J. R. O'Fallon, J. P. Colgan, J. D. Earle, R. L. Krigel, L. D. Brown, and W. J. McGinnis The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status Neuro-oncol, July 1, 1999; 1(3): 196 - 203. [Abstract] [PDF]

				B. Movsas, B. S. Y. Li, J. S. Babb, B. L. Fowble, N. Nicolaou, and O. Gonen Quantifying Radiation Therapy-induced Brain Injury with Whole-Brain Proton MR Spectroscopy: Initial Observations Radiology, November 1, 2001; 221(2): 327 - 331. [Abstract] [Full Text] [PDF]